Endocrine Abstracts

Background: Insulin resistance is a hallmark of Polycystic Ovary Syndrome (PCOS). Insulin sensitisers, most notably metformin, are thus used to treat the condition, but may be accompanied by gastrointestinal side-effects. The novel isomeric insulin sensitising agents D-chiro-inositol (DCI) and Myo-inositol (MI) improve insulin resistance by acting at the peripheral and ovarian level, respectively, whilst largely being devoid of adverse effects.<p class="...

Background: Insulin resistance is a hallmark of Polycystic Ovary Syndrome (PCOS). Insulin sensitisers, most notably metformin, are thus used to treat the condition, but may be accompanied by gastrointestinal side-effects. The novel isomeric insulin sensitising agents D-chiro-inositol (DCI) and Myo-inositol (MI) improve insulin resistance by acting at the peripheral and ovarian level, respectively, whilst largely being devoid of adverse effects.<p class="...